Skip to main content

Adverse event profiles of immune checkpoint inhibitor-based strategies for metastatic prostate cancer: a systematic review and network meta-analysis

In brief

Adding checkpoint inhibitors to endocrine therapy nearly tripled severe adverse events

Across 10 randomized trials involving 8,197 people with metastatic prostate cancer, adding an immune checkpoint inhibitor to endocrine therapy was linked to nearly three times as many severe adverse events and more serious and fatal events. Those estimates are uncertain, and indirect comparisons do not establish which regimen is safest; head-to-head trials with consistent safety reporting are needed.

Journal
Frontiers in medicine (Q1)
Published
30 October 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Qingyuan Wang, Chuang Hao, Jun Chen, Wenzhi Wang, Hao Zhang
PMID
43031762
DOI
10.3389/fmed.2026.1904711

Why clinicians should know about it

  • Picked for Urology (top studies of the week, 15 November 2026): Systematic comparison of immunotherapy toxicity in metastatic prostate cancer

Abstract

BACKGROUND: Immune checkpoint inhibitor (ICI)-based combination strategies are increasingly evaluated in metastatic prostate cancer (mPCa), but their comparative safety profiles remain uncertain. We conducted a systematic review and network meta-analysis (NMA) to compare adverse event (AE) profiles of ICI-based strategies in mPCa. METHODS: PubMed, Embase, Cochrane Library, and Web of Science were searched. Ten randomized trials involving 8,197 participants and seven predefined treatment nodes were analyzed. Outcomes included any-grade AEs, grade ≥3 AEs, serious AEs, fatal AEs, any-cause AEs, and selected organ-specific immune-related AEs (diarrhea, rash, hypothyroidism, fatigue). Random-effects NMA estimated odds ratios (ORs) with 95% confidence intervals (CIs). SUCRA values were considered exploratory only. Transitivity was assessed qualitatively, and sensitivity analysis excluded metastatic hormone-sensitive prostate cancer (mHSPC) trials. Certainty was summarized using a structured qualitative assessment. RESULTS: All outcome networks were star-shaped, with no closed loops; therefore, loop inconsistency could not be formally assessed. In the endocrine-therapy subgroup, adding an ICI to an ARPI-based endocrine backbone significantly increased any-grade AEs (OR 1.33, 95% CI 1.19-1.47), grade ≥3 AEs (OR 2.85, 2.36-3.45), serious AEs (OR 5.33, 3.89-7.31), and fatal AEs (OR 8.03, 1.84-35.02), but not any-cause AEs (OR 1.04, 0.92-1.18). Across the NMA, CTLA-4-containing regimens and PD-(L)1 plus endocrine therapy showed less favorable signals for serious and fatal AEs, whereas PD-1 plus chemotherapy ranked relatively favorably in exploratory SUCRA analyses for several outcomes. However, fatal-event estimates were based on few events, several CIs were wide, and sensitivity analysis excluding mHSPC trials changed the precision and, for some comparisons, the direction or statistical significance of estimates. CONCLUSIONS: In this exploratory NMA, ICI-based combination strategies in mPCa showed heterogeneous safety profiles. Adding ICIs to endocrine therapy was associated with increased AEs. PD-1 plus chemotherapy ranked relatively favorably in exploratory SUCRA analyses, but this should not be interpreted as confirmed safety superiority, and no regimen should be regarded as definitively safest. Certainty was limited by sparse, predominantly star-shaped networks, indirect comparisons, variable AE definitions, and imprecise estimates. Head-to-head randomized trials with standardized safety reporting are needed. SYSTEMATIC REVIEW REGISTRATION: PROSPERO identifier CRD420261342375.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.